🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesSOUL trial preliminary data — November 2025 Page 2

SOUL trial preliminary data — November 2025

JenMemphis Sun, Mar 16, 2025 at 2:50 AM 51 replies 2,130 viewsPage 2 of 11
mike.trainer_LA
Senior Member
1,567
7,234
Apr 2024
Los Angeles, CA
Mar 16, 2025 at 4:10 PM#6
BariatricNurseD said:
Relative and absolute effects need reading together.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them. The results probably generalise, and "probably" should be stated as an assumption rather than dropped.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

Last edited: Mar 16, 2025 at 8:10 PM
19 22Dr.AddMedPHL, newstart_MO, mia_MS2 and 16 others
Reply Quote Save Share Report
anders_CPH
Senior Member
1,567
7,234
Feb 2024
Copenhagen, DK
Mar 16, 2025 at 9:26 PM#7
JenMemphis said:
My own curve sits about four points below the published mean and I spent two months assuming that meant something was wrong with me or with my…

Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational studies can provide useful evidence.

A recent PSM study of 18,000 GLP-1 users vs matched controls showed reduced all-cause mortality (HR 0.81) over 4 years of follow-up[1].

These results complement the RCT data and suggest the benefits translate to real-world populations.

References:
[1] Registry-based cohort study, pre-print 2024.
Last edited: Mar 17, 2025 at 1:26 AM
20 23MariaRD, AussieAnna, BethLabQueen and 17 others
Reply Quote Save Share Report
newstart_MO
New Member
12
45
Feb 2026
Springfield, MO
Mar 17, 2025 at 2:42 AM#8
mike.trainer_LA said:
I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them.

Forest plot interpretation for the the trial evidence meta-analysis: when reading the pooled estimate, pay attention to:

  1. Point estimate (HR/RR/OR) — center of the diamond
  2. Confidence interval width — precision of the estimate
  3. I² statistic — heterogeneity across studies
  4. Individual study weights — are results driven by one large trial?
  5. Prediction interval — range of plausible true effects in future settings

The the trial evidence meta-analysis shows a pooled RR of 0.80 (95% CI 0.65-0.90), I²=38%. This is a robust and consistent effect.

Last edited: Mar 17, 2025 at 8:42 AM
21 24HPLC_Greg, LibrarianMeg, bri_stats and 18 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
mia_MS2
New Member
8
23
Jun 2026
Ann Arbor, MI
Mar 17, 2025 at 7:58 AM#9

A narrower follow-up, since the general answer is now clear:

What would you measure differently if you were starting again?

Last edited: Mar 17, 2025 at 10:58 AM
22 0steve_okc, dave_SLC, FDA_TrackerJim and 19 others
Reply Quote Save Share Report
JenMemphis
Member
267
1,234
Jan 2025
Memphis, TN
Mar 18, 2025 at 9:12 AM#10

OP back with an update, since a thread like this is useless without one.

Follow-up: I read the paper rather than the summary and the qualifier I was missing was in the second paragraph of the results.

Last edited: Mar 18, 2025 at 2:12 PM
22 20LarryQC_SD, wanda_boise, NurseAsh_DET and 19 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register